THNKase (tenecteplace) is a single-dose intravenous bolus that is faster and easier to administer than the only other existing drug on the market, Activase (alteplase) – and it comes nearly 30 ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

It is the second FDA-approved treatment for acute ischemic stroke, the other being Activase (alteplase), also manufactured by Genentech, the release said. Tenecteplase is the first acute ischemic ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness ...

As a result of the approval, Genentech has the only two FDA-approved medicines to treat AIS in its portfolio, namely TNKase and Activase (alteplase). TNKase is a tissue plasminogen activator ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

TNKase will be available for the treatment of acute ischemic stroke in adults, joining the Roche subsidiary’s Activase ...

This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a 60-minute infusion. Genentech, the manufacturer of TNKase ...

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates.

The approval is based on a large multi-center non-inferiority study demonstrating that TNKase is comparable to Activase in AIS patients in terms of safety and efficacy. The AcT (Alteplase compared ...